23 references, page 1 of 2
Addolorato G.Leggio L.Agabio R.Colombo G.Gasbarrini G. (2006). Baclofen: a new drug for the treatment of alcohol dependence. Int. J. Clin. Pract. 60, 1003–1008 16893442 [PubMed]
Addolorato G.Leggio L.Cardone S.Ferrulli A.Gasbarrini G. (2009). Role of the GABA (B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol 43, 559–563 10.1016/j.alcohol.2009.09.031 19913201 [OpenAIRE] [PubMed] [DOI]
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th Edn. Washington, DC: American Psychiatric Association
Black D. (2004). An open-label trial of bupropion in the treatment of pathological gambling. J. Clin. Psychopharmacol. 24, 108–109 10.1097/01.jcp.0000114844.58996.4a 14709965 [OpenAIRE] [PubMed] [DOI]
Blanco C.Petkova E.Ibanez A.Sáiz-Ruiz J. (2002). A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann. Clin. Psychiatry 14, 9–15 12046642 [OpenAIRE] [PubMed]
Boothby L. A.Doering P. L. (2005). Acamprosate for the treatment of alcohol dependence. Clin. Ther. 27, 695–714 16117977 [OpenAIRE] [PubMed]
Dannon P. N.Lowengrub K.Gonopolski Y.Musin E.Kotler M. (2006). Pathological gambling: a review of phenomenological models and treatment modalities for an under recognized psychiatric disorder. Prim Care Companion J. Clin. Psychiatry 8, 334–339 17245454 [OpenAIRE] [PubMed]
Dannon P. N.Lowengrub K.Musin E.Gonopolski Y.Kotler M. (2005a). Sustained release Bupropion versus nalt rexone in the treatment of pathological gambling. J. Clin. Psychopharmacol. 25, 593–596 16282845 [OpenAIRE] [PubMed]
Dannon P. N.Lowengrub K.Gonopolski Y.Musin E.Kotler M. (2005b). Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin. Neuropharmacol. 28, 6–10 15711432 [OpenAIRE] [PubMed]
Dannon P. N.Lowengrub K.Musin E.Gonoposki Y.Kotler M. (2005c). Sustained release bupropion in the treatment of SSRI no responder pathological gamblers: pilot study and review of the literature. Therapy 2, 753–759
Dannon P. N.Lowengr ub K.Musin E.Gonopolski Y.Kotler M. (2007). 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J. Clin. Psychopharmacol. 27, 620–624 18004130 [PubMed]
Grant J. E.Kim S. W.Potenza M. N.Blanco C.Ibanez A.Stevens L.Hektner J. M.Zaninelli R. (2003). Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int. Clin. Psychopharmacol. 18, 243–249 12817159 [PubMed]
Guy W. (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Publication (ADM), 76–338
Hamilton M. (1959). The assessment of anxiety states by rating. Br. J. Med. Psychol. 32, 50–55 13638508 [PubMed]
Hamilton M. (1960). A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 56–62 14399272 [OpenAIRE] [PubMed]
23 references, page 1 of 2